The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis

This study has been completed.
Sponsor:
Information provided by:
Samsung Medical Center
ClinicalTrials.gov Identifier:
NCT01171768
First received: July 16, 2010
Last updated: July 20, 2011
Last verified: July 2011

July 16, 2010
July 20, 2011
June 2008
Not Provided
serum VEGF and Ang-2 level in lung inflammatory disease according to the presence of hemoptysis [ Time Frame: up to 7 days after enrollment ] [ Designated as safety issue: Yes ]
We'll measure the serum VEFG and Ang-2 level of enrolled patients within a week from the moment that patients agree to enroll this study. Therefore, Comparison of the serum VEGF and Ang-2 level (measured within a week from enrollment) according to the presence of hemoptysis will be primary outcome.
Same as current
Complete list of historical versions of study NCT01171768 on ClinicalTrials.gov Archive Site
to investigate association between angiogenesis factors and other factors such as inflammatory biomarker and hypoxia. [ Time Frame: up to 7 days after enrollment ] [ Designated as safety issue: Yes ]
We'll measure the serum VEFG, Ang-2 level, and other factors such as inflammatory biomarkers and PaO2 of enrolled patients within a week from the moment that patients agree to enroll this study. Therefore, Investigating association between angiogensis factors and other factors such as inflammatory biomarker and hypoxia, which were measured within a week from enrollment, will be secondary outcome.
Same as current
Not Provided
Not Provided
 
The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis
The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis

Vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) are major mediators of angiogenesis and are induced by tissue inflammation and hypoxia. While elevated serum VEGF levels have been reported in inflammatory lung diseases, especially with hemoptysis, there was no study to evaluate the Ang-2 levels in lung inflammatory diseases according to the presence of hemoptysis, inflammatory biomarker and hypoxia.

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

patients visited Samsung Medical Center for the treatment of benign inflammatory disease such as bronchiectasis, aspergilloma, peumonia and post-tuberculosis destroyed lung

  • Inflammatory Lung Diseases
  • Hemoptysis
Not Provided
  • patients with hemoptysis within 2 weeks
  • patients without hemoptysis within 2 years
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
52
December 2010
Not Provided

Inclusion Criteria:

  • patients visited Samsung Medical Center for the treatment of benign inflammatory disease such as bronchiectasis, aspergilloma, pneumonia and post-tuberculosis destroyed lung

Exclusion Criteria:

  • patients with tumorous condition including lung cancer, vasculitis and the lung disease associated with collagen vascular disease on the point of enrollment
Both
20 Years to 90 Years
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
NCT01171768
2008-05-043
Not Provided
Sang-Won Um, Samsung Medical Center
Samsung Medical Center
Not Provided
Not Provided
Samsung Medical Center
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP